It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID-19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID-19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen-6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non-expensive bioindicators showed a good accuracy in discriminating between severe and non-severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers' panel, including lymphocyte cell counts and KL-6, may be useful in the clinical management of severe COVID-19 patients. This article is protected by copyright. All rights reserved.

D'Alessandro, M., Bergantini, L., Cameli, P., Curatola, G., Remediani, L., Sestini, P., et al. (2021). Peripheral biomarkers' panel for severe COVID-19 patients. JOURNAL OF MEDICAL VIROLOGY, 93(3), 1230-1232 [10.1002/jmv.26577].

Peripheral biomarkers' panel for severe COVID-19 patients

d'Alessandro M.;Bergantini L.;Cameli P.;Sestini P.;Bargagli E.;Bennett D.
Membro del Collaboration Group
;
Lanzarone N.
Membro del Collaboration Group
;
Montagnani F.
Membro del Collaboration Group
;
Franchi F.
Membro del Collaboration Group
;
Scolletta S.
Membro del Collaboration Group
;
Mazzei M. A.
Membro del Collaboration Group
;
Volterrani L.
Membro del Collaboration Group
;
Zanelli G.
Membro del Collaboration Group
;
Capecchi P. L.
Membro del Collaboration Group
;
Cusi M. G.
Membro del Collaboration Group
;
Frediani B.
Membro del Collaboration Group
;
Cameli M.
Membro del Collaboration Group
;
Guerrini S.
Membro del Collaboration Group
;
Caffarelli C.
Membro del Collaboration Group
;
Gonnelli S.
Membro del Collaboration Group
;
Ceccarelli E.
Membro del Collaboration Group
;
Conticini E.
Membro del Collaboration Group
;
Cantarini L.
Membro del Collaboration Group
;
2021-01-01

Abstract

It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID-19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID-19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen-6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non-expensive bioindicators showed a good accuracy in discriminating between severe and non-severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers' panel, including lymphocyte cell counts and KL-6, may be useful in the clinical management of severe COVID-19 patients. This article is protected by copyright. All rights reserved.
D'Alessandro, M., Bergantini, L., Cameli, P., Curatola, G., Remediani, L., Sestini, P., et al. (2021). Peripheral biomarkers' panel for severe COVID-19 patients. JOURNAL OF MEDICAL VIROLOGY, 93(3), 1230-1232 [10.1002/jmv.26577].
File in questo prodotto:
File Dimensione Formato  
peripheral biomarkers.pdf

non disponibili

Descrizione: Free full-text sul sito dell'editore e su PMC per la durata della pandemia
Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.05 MB
Formato Adobe PDF
1.05 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1117228